GlassScriptPhysician profile
Abigail M Voss
NPI 1013284934
$1,571.63
in general payments reported to CMS, 2019-2025
22 companies · $340 in 2025
The $340 reported for 2025 was more than what a typical Primary Care provider received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $320 · 2022: $228 · 2023: $367 · 2024: $317 · 2025: $340.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,024.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,024.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $190.45 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Radius Health, INC. | $178.06 | 2021-2025 | |
| Abbvie INC. | $142.45 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $139.98 | 2021-2024 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Otsuka America Pharmaceutical, INC. | $127.12 | 2024-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Astrazeneca Pharmaceuticals LP | $87.76 | 2021-2025 | Airsupra |
| Amgen INC. | $87.42 | 2023-2025 | Evenity, Repatha, Prolia |
| Takeda Pharmaceuticals U.S.A., INC. | $86.77 | 2021-2024 | Trintellix |
| Lilly USA, LLC | $75.17 | 2022-2025 | Mounjaro, Zepbound |
| Merck Sharp & Dohme LLC | $64.35 | 2021-2022 | |
| Exact Sciences Corporation | $59.90 | 2023 | Cologuard Collection Kit |
| Lundbeck LLC | $51.91 | 2022-2024 | Rexulti |
| Idorsia Pharmaceuticals US INC | $45.21 | 2022-2023 | Quviviq |
| Dexcom, INC. | $37.23 | 2024 | Dexcom G6 Transmitter |
| E.R. Squibb & Sons, L.L.C. | $36.52 | 2024-2025 | Cobenfy |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $27.76 | 2025 | Gemtesa |
| Phathom Pharmaceuticals, INC. | $26.05 | 2023 | Voquezna |
| Pfizer INC. | $25.84 | 2021 | |
| Novartis Pharmaceuticals Corporation | $24.86 | 2023 | |
| Amarin Pharma, INC. | $21.05 | 2021 | |
| Xeris Pharmaceuticals, INC. | $20.23 | 2023 | Gvoke Hypopen |
| Glaxosmithkline, LLC. | $15.54 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abigail Voss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.